Clinical and immunologic effects of maraviroc in progressive multifocal leukoencephalopathy

Neurology. 2015 Jul 7;85(1):104-6. doi: 10.1212/WNL.0000000000001713. Epub 2015 Jun 3.

Authors

Ananja Middel¹, Joop E Arends², Steven F L van Lelyveld¹, Sigrid Otto¹, Rob Schuurman¹, Catharina J M Frijns¹, Kiki Tesselaar¹, Andy I M Hoepelman¹

Affiliations

¹ From University Medical Center Utrecht (A.M., J.E.A., S.F.L.v.L., S.O., R.S., C.J.M.F., K.T., A.I.M.H.); University Medical Center Groningen (A.M.); and Kennemer Gasthuis (S.F.L.v.L.), Haarlem, the Netherlands.
² From University Medical Center Utrecht (A.M., J.E.A., S.F.L.v.L., S.O., R.S., C.J.M.F., K.T., A.I.M.H.); University Medical Center Groningen (A.M.); and Kennemer Gasthuis (S.F.L.v.L.), Haarlem, the Netherlands. j.e.arends@umcutrecht.nl.

PMID: 26041329
DOI: 10.1212/WNL.0000000000001713

No abstract available

MeSH terms

Aged
CCR5 Receptor Antagonists / pharmacology
CCR5 Receptor Antagonists / therapeutic use*
CD4-Positive T-Lymphocytes / drug effects
CD4-Positive T-Lymphocytes / immunology
Cyclohexanes / pharmacology
Cyclohexanes / therapeutic use*
Female
Humans
Leukoencephalopathy, Progressive Multifocal / diagnosis
Leukoencephalopathy, Progressive Multifocal / drug therapy*
Leukoencephalopathy, Progressive Multifocal / immunology*
Male
Maraviroc
Middle Aged
Treatment Outcome
Triazoles / pharmacology
Triazoles / therapeutic use*

Substances

CCR5 Receptor Antagonists
Cyclohexanes
Triazoles
Maraviroc